About Akouos
Akouos is a company based in Boston (United States) founded in 2016 was acquired by Lilly in October 2022. Akouos has raised $162.65 million across 4 funding rounds from investors including Fidelity Investments, Lilly and TD Securities. The company has 92 employees as of December 31, 2022. Akouos offers products and services including Gene Therapies. Akouos operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Boston, United States
- Employees 92 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Akouos, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$162.65 M (USD)
in 4 rounds
-
Latest Funding Round
$105.07 M (USD), Series B
Mar 03, 2020
-
Investors
Fidelity Investments
& 15 more
-
Employee Count
92
as on Dec 31, 2022
-
Acquired by
Lilly
(Oct 18, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Akouos
Akouos offers a comprehensive portfolio of products and services, including Gene Therapies.
Develop treatments to restore hearing through genetic interventions
People of Akouos
Unlock access to complete
Unlock access to complete
Funding Insights of Akouos
Akouos has successfully raised a total of $162.65M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $105.07 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Akouos
Akouos has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Lilly and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Akouos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Akouos
Investment portfolio details for Akouos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Akouos
Detailed financials for Akouos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Akouos Comparisons
Peer comparison for Akouos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Akouos
Akouos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
Detailed competitors of Akouos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Akouos
Complete news archive for Akouos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akouos
Akouos was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Akouos is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Akouos is a funded company, having raised a total of $162.65M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Akouos is 92.
Akouos was founded in 2016 in Boston, United States, within the biotechnology sector focused on auditory health. Gene therapies and delivery systems are developed to address hearing loss and balance disorders in specific genetic patient groups. Strategic licensing agreements have been established with Lonza and Massachusetts Eye and Ear for the Anc-AAV vector platform. Initial incubation occurred at Harvard Life Lab to support early operations.
Akouos's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Akouos offers Gene Therapies.
Akouos has 16 investors. Key investors include Fidelity Investments, Lilly, TD Securities, Citadel, and HHS.